Noubar Afeyan - BG Medicine Founder
| BGMDDelisted Stock | USD 0.0002 0.00 0.00% |
Founder
Dr. Noubar B. Afeyan Ph.D. is an Independent Director of BG Medicine Inc. since July 25 2011. He is founder and served as the Board of Directors since inception in 2000. He has served as Managing Partner and Chief Executive Officer of Flagship Ventures an early stage VC firm since he cofounded the firm in 2000. Prior to founding Flagship Ventures in 2000 Dr. Afeyan participated in cofounding and helping launch the following ventures PerSeptive Biosystems ChemGenics Pharmaceuticals EXACT Sciences Agenus Color Kinetics and Celera Genomics. Dr. Afeyan was Chief Executive Officer of PerSeptive Biosystems during its five years as a public company and until its merger with Perkin Elmer Corporationrationration. During the past five years Dr. Afeyan has served on the board of directors of Helicos BioSciences. Additionally he currently serves as a director of the following private companies Affinnova Inc. Aero Designs BIND Therapeutics Inc. Eleven Biotherapeutics Ensemble Therapeutics Joule Unlimited Inc. LS9 Inc. Moderna Therapeutics and Pronutria. He earned his Ph.D. in biochemical engineering from the Massachusetts Institute of Technology following a B.S. in chemical engineering from McGill University. Dr. Afeyan has authored numerous scientific publications and patents and is currently a Senior Lecturer at MIT in the Sloan School of Management since 2011.
| Age | 52 |
| Tenure | 13 years |
| Phone | 781 890 1199 |
| Web | https://www.bg-medicine.com |
BG Medicine Management Efficiency
The company has return on total asset (ROA) of (0.7595) % which means that it has lost $0.7595 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (9.0264) %, meaning that it created substantial loss on money invested by shareholders. BG Medicine's management efficiency ratios could be used to measure how well BG Medicine manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 2 records | FOUNDER Age | ||
| David Cohen | Innovative Eyewear | 51 | |
| Konrad Dabrowski | Innovative Eyewear | 41 | |
Management Performance
| Return On Equity | -9.03 | ||||
| Return On Asset | -0.76 |
BG Medicine Leadership Team
Elected by the shareholders, the BG Medicine's board of directors comprises two types of representatives: BG Medicine inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BGMD. The board's role is to monitor BG Medicine's management team and ensure that shareholders' interests are well served. BG Medicine's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BG Medicine's outside directors are responsible for providing unbiased perspectives on the board's policies.
| James Connor, Director | ||
| Harry Wilcox, Director | ||
| Stelios Papadopoulos, Independent Director | ||
| Aram Adourian, Chief Scientific Officer and Sr. VP | ||
| Stephen Hall, CFO, Principal Accounting Officer, Executive VP and Treasurer | ||
| Jeffrey Luber, Director | ||
| Paul Sohmer, President CEO, Director | ||
| Noubar Afeyan, Founder | ||
| James OConnor, Independent Director |
BGMD Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is BG Medicine a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -9.03 | ||||
| Return On Asset | -0.76 | ||||
| Operating Margin | (2.86) % | ||||
| Current Valuation | 545.97 K | ||||
| Shares Outstanding | 11.37 M | ||||
| Number Of Shares Shorted | 630.05 K | ||||
| Price To Earning | (0.06) X | ||||
| Price To Sales | 0.35 X | ||||
| Revenue | 1.57 M | ||||
| Gross Profit | 1.06 M |
Pair Trading with BG Medicine
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BG Medicine position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BG Medicine will appreciate offsetting losses from the drop in the long position's value.Moving against BGMD Pink Sheet
| 0.58 | YS | YS Biopharma Report 22nd of April 2024 | PairCorr |
The ability to find closely correlated positions to BG Medicine could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BG Medicine when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BG Medicine - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BG Medicine to buy it.
The correlation of BG Medicine is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BG Medicine moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BG Medicine moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BG Medicine can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Other Consideration for investing in BGMD Pink Sheet
If you are still planning to invest in BG Medicine check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the BG Medicine's history and understand the potential risks before investing.
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |